



The Development of Adjuvanted Recombinant Vaccines against Infectious Diseases

Guest Editor:

Prof. Dr. Abu Salim Mustafa

Department of Microbiology,
College of Medicine, Health
Sciences Centre, Kuwait
University, Kuwait City, Kuwait

Deadline for manuscript
submissions:

31 March 2025

Message from the Guest Editor

Dear Colleagues,

While significant progress has been made in preventing and controlling infectious diseases globally, humanity continues to suffer from their devastating effects. Vaccines play a crucial role in combating infectious diseases. Many successful vaccines have been developed to immunize against human infectious diseases, thereby reducing morbidity and mortality. One strategy for developing new and more effective vaccines involves using immunogenic proteins in the form of recombinant vaccines. However, recombinant proteins are generally weak antigens and necessitate appropriate adjuvants and delivery systems to enhance their protective efficacy. Incorporating adjuvants can reduce the antigens required to elicit an optimal immune response, thereby minimizing adverse effects at the inoculation site.

This Special Issue invites original research and review articles on the efficacy of adjuvanted recombinant vaccines in preclinical and clinical trials against bacterial, parasitic, fungal, and viral infections for consideration.

Prof. Dr. Abu Salim Mustafa
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com